NewsEvents

Your Yourlocation: Home > Depth analysis of tiotropium bromide(136310-93-5) inhalant market

M receptor blockers inhalers accounted for 17% of the total market, on behalf of the products are ipratropium bromide, tiotropium bromide(136310-93-5), glibenclamide and albibromide. In the four products, except for ipratropium bromide is the inhalation solution, the rest are DPI. On the market side, albiconium bromide and gerberan bromide have just been listed and have not yet hit the market. BI tiotropium bromide(136310-93-5) and ipratropium bromide are still the dominant brands in the market.

M receptor blockers + β2 receptor agonists inhalers is a relatively new category, has not caused a great impact on the market, the market in 2014 accounted for 2%. Representative products are ipratropium bromide + Combivent, Globe Bromide + Ultibro, ipridibromide + Duaklir, Umea bromide + Anoro.

According to the Chinese Medical Association's "Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Diseases (2013)" shows that the incidence of COPD in our population over 40 years of age is as high as 8.2%, COPD will be the third leading cause of death after 2020. There are no technical barriers to the development of inhalants. According to the FDA guidelines, the main contents of the inhalants study are aerodynamic particle size distribution, delivery dose uniformity, delivery dose and content uniformity, and the evaluation of these parameters such as ACI /NGI, DUSA in the country have been able to buy. The difficulty of developing inhalants is that the cost of research and development is high. First, the dosage of the inhalant is low and the common liquid phase is difficult to be detected. It may be necessary to use the equipment with higher detection limit, such as LC-MS. Second, the industrial equipment is expensive. Third is to do bioequivalence and treatment equivalence related to clinical research.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved